Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PDL1 and CXCR4

Antibodies and derivative drugs targeting immune checkpoints have been approved for the treatment of several malignancies, but there are fewer responses in patients with pancreatic cancer.